Solid Organ Transplant Nursing Guide

Transplant Principles

Organ Donation Types

DBD Donation after Brain Death

Brainstem death confirmed by 2 senior clinicians using formal criteria (absent brainstem reflexes, apnoea test). Heart still beating, optimal organ perfusion. All solid organs potentially viable.

DCD Donation after Circulatory Death

Cardiac arrest occurs; warm ischaemia time is critical. Controlled (Maastricht III — planned WLST) vs uncontrolled (Maastricht II — failed CPR). Increases warm ischaemia — kidneys & liver most used; hearts now possible with NRP.

Living Donor

Related (family) or unrelated (paired exchange). Laparoscopic donor nephrectomy standard. Rigorous psychological and medical evaluation mandatory. Living donors have slightly better outcomes for recipients.

HLA Matching & Crossmatch

HLA system: Human Leukocyte Antigens — class I (A, B, C) and class II (DR, DQ, DP). Mismatches trigger immune rejection. Zero-mismatch kidneys have best long-term outcomes.

Virtual crossmatchIn silico — HLA antibody screen vs donor HLA

CDC crossmatchComplement-dependent cytotoxicity

Flow cytometry XMMost sensitive — detects low-level DSA

Positive crossmatch = contraindication to transplant. DSA (Donor Specific Antibodies) monitored post-transplant by Luminex single-antigen bead testing.

Organ Preservation & Cold Ischaemia Times

Cold ischaemia time (CIT) = perfusion with cold preservation solution to reperfusion. Shorter is better.

🫘 Kidney 24–36 hours

🫁 Liver 12–24 hours

🫀 Heart 4–6 hours

🫁 Lung 4–6 hours

Preservation solutions: University of Wisconsin (UW) / HTK (Custodiol) / Celsior. Machine perfusion (normothermic/hypothermic) extends viability, especially DCD livers.

Allocation Systems

UNOS (USA): United Network for Organ Sharing. Kidneys by PRA (panel reactive antibody), waiting time, HLA mismatch, distance. Hearts/lungs by urgency status (Status 1A/1B).

Eurotransplant: Covers 8 European countries. ETKAS for kidneys — points for HLA match, waiting time, sensitisation. ETAS for high-urgency cases.

UK — NHS Blood & Transplant: National allocation for deceased donors. Kidney Offering Scheme (KOS) 2023.

GCC: Saudi Center for Organ Transplantation (SCOT) coordinates allocation in KSA. Individual national programmes in UAE, Qatar, Kuwait.

Donor Work-up & Consent

Deceased donor work-up:

Blood group & HLA typing
Serology: HIV, HBV, HCV, CMV, EBV, Syphilis, HTLV
Renal function (creatinine, eGFR), LFTs, cardiac echo
Imaging: CXR, renal USS, angiography if indicated
Urine & blood cultures — rule out active infection
Biopsy for marginal kidneys (donor age >65)

Donor Family Care: Specialist Nurses in Organ Donation (SNOD) / Donor Coordinators provide sensitive communication, support grieving families, present donation as a gift of life. Cultural and religious sensitivity essential — especially in GCC context.

Ischaemia-Reperfusion Injury (IRI)

IRI occurs when blood flow is restored to an ischaemic organ — paradoxical cell death due to reactive oxygen species (ROS), neutrophil activation, complement activation.

Phases of IRI:

1. Ischaemic phase: ATP depletion, cellular acidosis, Na+/K+ pump failure → cell swelling

2. Reperfusion phase: ROS burst, Ca2+ overload, complement activation, DAMP release → inflammation & cell death

Clinical consequence: Delayed Graft Function (DGF) in kidneys, primary non-function, early allograft dysfunction in liver. Mitigated by minimising cold/warm ischaemia, machine perfusion, conditioning strategies.

Kidney Transplant Nursing

Pre-operative Preparation

Dialysis access: Assess AVF/AVG — fistula arm must be protected intraoperatively; discuss long-term removal planning if graft functions
Bladder function assessment: Urodynamics if history of voiding dysfunction, posterior urethral valves, or neurogenic bladder; augmentation cystoplasty may be needed
Fluid status: Aim euvolaemia; HD patients may need dialysis to remove excess fluid pre-op
Medications: Immunosuppression induction given (basiliximab/ATG); tacrolimus/MMF/prednisolone started
Baseline bloods: FBC, U&E, LFT, clotting, crossmatch, HbA1c
IV access: Large-bore cannula; avoid AVF arm for all venepuncture
Bowel prep / catheter: Urinary catheter (Foley 3-way if bladder irrigation needed)

Peri-operative Monitoring

TARGET

Urine Output >50 ml/hr

Hourly urine measurement is the primary early graft function indicator. Brisk diuresis (100-300 ml/hr) normal initially — may need IV fluid replacement.

JVP/CVP monitoring: Adequate filling essential — keep CVP 8–12 cmH₂O. Hypovolaemia → reduced graft perfusion → DGF. Avoid excessive fluid → pulmonary oedema.

Blood pressure: Systolic 120–160 mmHg; avoid hypotension (graft thrombosis risk). MAP >70 mmHg.

Wound: Iliac fossa incision monitoring — assess for bleeding/haematoma. Jackson-Pratt drain output documented.

Electrolytes: Potassium — hyperkalaemia common if DGF; serial ECGs if K+ >5.5. Glucose — tacrolimus-induced hyperglycaemia common.

Immediate Post-op Complications

Delayed Graft Function (DGF)

Dialysis required within 1st week. Due to IRI, prolonged CIT, DCD organ. Management: continue dialysis, optimise fluids, repeat biopsy if persistent >4 weeks.

Primary Non-Function (PNF)

Kidney never functions — rare. Causes: unrecognised vascular thrombosis, hyperacute rejection, severe IRI. May require transplant nephrectomy.

Vascular Thrombosis

Renal artery/vein thrombosis — sudden cessation of urine output, graft pain/tenderness. URGENT USS Doppler. Surgical emergency.

Urological Complications

Urine leak (vesico-ureteric anastomosis failure), ureteric obstruction (stricture, lymphocele). USS/renogram for diagnosis.

Bleeding / Haematoma

Monitor drain output, Hb trends, wound swelling. Return to theatre if significant.

Rejection Types

Hyperacute Rejection

Minutes–hours. Pre-formed antibodies (ABO incompatibility, DSA). Graft turns blue intraoperatively. Irreversible — transplant nephrectomy required. Prevented by crossmatch.

Acute Cellular Rejection (ACR)

Days–weeks post-transplant. T-cell mediated. Rising creatinine, oliguria, graft tenderness, fever. Biopsy: tubulitis, interstitial infiltrate (Banff criteria). Tx: IV methylprednisolone 500mg x3.

Antibody-Mediated Rejection (ABMR)

Any time. DSA, C4d deposition on biopsy, peritubular capillaritis. Tx: plasmapheresis, IVIG, rituximab. Harder to treat than ACR.

Chronic Allograft Nephropathy

Months–years. Slow creatinine rise, proteinuria, hypertension. Biopsy: interstitial fibrosis, tubular atrophy (IF/TA). No specific treatment — optimise immunosuppression, BP, avoid nephrotoxins.

Renal USS Doppler & Biopsy Nursing Care

Transplant Renal USS Doppler

Performed at 24–48h post-op, then as clinically indicated
Resistive Index (RI) normal: 0.6–0.8
RI >0.8: rejection, obstruction, ATN, venous thrombosis
Absent/reversed diastolic flow: vascular emergency
Assess for hydronephrosis, perinephric collections
Nurse prep: patient NBM not required, explain procedure

Transplant Biopsy Nursing Care

Consent, clotting screen (INR <1.3, platelets >80), hold anticoagulants
USS-guided — graft easily accessible (iliac fossa)
Post-biopsy: bed rest 4–6h, observations Q15min x1h then Q30min x4h
Monitor: haematuria, loin pain, hypotension, haematoma
Urine dip post-procedure — macroscopic haematuria = concern
Results reported using Banff classification

Immunosuppression Management

Triple Therapy — Standard Maintenance Protocol

Tacrolimus (FK506)

Calcineurin inhibitor — inhibits IL-2 production → blocks T-cell activation. Trough levels monitored (target varies: 8–12 ng/ml early, 5–8 ng/ml maintenance). Given BD.

Mycophenolate Mofetil (MMF)

Antiproliferative — inhibits IMPDH → blocks purine synthesis → suppresses B and T cell proliferation. 500–1500mg BD. Converted to MPA (active form).

Prednisolone

Corticosteroid — broad anti-inflammatory and immunosuppressive. High dose induction then taper. Many centres target <10mg/day by 3 months. Some protocols steroid-free after 1 year.

Adherence is Critical: Even one missed dose can trigger rejection. Nurses must educate patients on never stopping medications without medical advice. Link poor adherence to loss of graft — often affects younger patients. Pharmacist-led medication reconciliation on every admission.

Time Post-Transplant	Target Trough (ng/ml)	Interpretation
0–3 months	8–12 ng/ml	High immunosuppression needed — rejection risk highest
3–12 months	6–10 ng/ml	Tapering phase — balance rejection vs toxicity
>12 months (stable)	4–8 ng/ml	Maintenance — minimise long-term toxicity
>20 ng/ml (toxic)	HOLD / REDUCE	Nephrotoxicity / neurotoxicity risk — inform physician

Liver & Heart Transplant

Liver Transplant — Listing Criteria

MELD Score (USA)

Model for End-stage Liver Disease. Calculated from creatinine, bilirubin, INR, sodium. Score 6–40. Higher score = higher 90-day mortality = higher priority for transplant. Score >15: transplant benefit exceeds medical management.

UKELD Score (UK)

UK End-stage Liver Disease score — incorporates Na+, creatinine, bilirubin, INR. Score >49 required for listing (predicts >9% 1-year mortality without transplant). Exception points system for HCC, cholangiocarcinoma.

Common indications: Alcoholic liver disease (6 months abstinence), NASH cirrhosis, PSC, PBC, hepatitis B/C, hepatocellular carcinoma (Milan criteria: 1 lesion <5cm or 3 lesions <3cm each), acute liver failure (King's College criteria).

Liver Transplant — Biliary Complications

Hepatic Artery Thrombosis (HAT)

Most serious early complication — 3–5% incidence. HAT = biliary infarction (bile duct depends on hepatic artery). Presents with sudden LFT rise, biliary sepsis, or graft failure. URGENT USS Doppler. Surgical intervention (thrombectomy/re-transplant) needed. Late HAT: biloma, biliary strictures, recurrent cholangitis.

Bile Leak

Early complication — anastomotic leak, T-tube removal, cut surface of partial grafts. Presents: bilious drain output, pain, peritonism, rising bilirubin. Diagnosed: ERCP, MRCP, radionucleotide scan. Tx: ERCP + stent / surgical repair.

Biliary Stricture

Anastomotic (early — technical) or ischaemic (late — from HAT, DCD organ). Presents with cholestasis, jaundice, cholangitis. MRCP for diagnosis. Tx: ERCP + balloon dilatation/stenting. Refractory: Hepaticojejunostomy revision or re-transplant (ischaemic cholangiopathy).

Early Liver Function Recovery — Monitoring

LFTs monitored daily in first week to track graft recovery and detect complications.

AST / ALT

Peak 24–48h
Trend down = good function

Bilirubin

Should fall by Day 5–7
Rising = biliary/graft problem

INR / PT

Normalises Day 3–5
Persistent elevation = poor function

Glucose / Lactate

Glucose stable
Lactate clearing = good sign

Bile output

Golden bile = functioning
Colourless = poor function/obstruction

Heart Transplant — Key Concepts

Cardiac Allograft Vasculopathy (CAV)

Diffuse accelerated coronary artery disease — leading cause of death after 1st year. Immune-mediated intimal hyperplasia. Detected by annual coronary angiography +/- IVUS. No angina warning (denervated heart). Presentation: silent MI, sudden death, graft failure. mTOR inhibitors (everolimus) may slow progression.

Endomyocardial Biopsy (EMB)

Gold standard for rejection monitoring. Via right internal jugular vein — right ventricular septal biopsies. ISHLT grading: Grade 0 = no rejection, Grade 1A/1B = mild, Grade 2 = moderate (treat), Grade 3A/3B = severe. Nurse: post-procedure monitor for cardiac tamponade (JVP rise, hypotension, muffled heart sounds).

Cardiac Denervation

Transplanted heart is denervated — no autonomic nerve supply. Consequences: resting HR 90–110 bpm (normal), no angina with ischaemia, exercise HR increase delayed and relies on circulating catecholamines. Atropine ineffective for bradycardia — use isoprenaline or pacing.

Heart Tx Immunosuppression

Tacrolimus + MMF + Prednisolone (same triple therapy). CMV prophylaxis essential (D+/R− very high risk). More intensive early immunosuppression than kidney transplant. Induction with basiliximab or rabbit ATG.

Post-Transplant Complications

Infection — CMV

DNA virus Most common OI post-Tx

Presentation: Fever, malaise, leucopaenia, thrombocytopaenia. Tissue-invasive: pneumonitis, hepatitis, colitis, retinitis, encephalitis.

Diagnosis: CMV PCR (quantitative DNA in blood), pp65 antigenaemia. Tissue biopsy for end-organ disease.

Treatment: IV Ganciclovir (inpatient) or oral Valganciclovir. Duration guided by PCR negativity (usually 2 consecutive negative results 1 week apart).

Monitoring: Weekly CMV PCR during prophylaxis period and 3 months post-prophylaxis. FBC monitoring — ganciclovir causes leucopaenia.

Infection — PCP & Fungal

Pneumocystis jirovecii Pneumonia (PCP)

Dry cough, progressive dyspnoea, fever, bilateral perihilar shadowing on CXR/CT (ground-glass). Diagnosed by BAL immunofluorescence / PCR. Tx: high-dose co-trimoxazole IV. Reduce immunosuppression.

Candidiasis

Oropharyngeal (oral thrush), oesophageal, urinary tract, candidaemia. Tx: fluconazole (Candida albicans), echinocandins (resistant species, Candida glabrata). Blood cultures for invasive disease.

Invasive Aspergillosis

High mortality — especially lung transplant recipients. Presents with sinusitis, pulmonary infiltrates, haemoptysis. CT: halo sign. Galactomannan antigen test. Tx: Voriconazole (drug interaction with tacrolimus — level rises dramatically).

Metabolic Complications

NODAT — New-Onset Diabetes After Transplant

Incidence 15–25%. Risk factors: tacrolimus (beta cell toxicity), steroids (insulin resistance), older age, overweight, family history, CMV infection. Monitor: fasting glucose, HbA1c at every clinic. Tx: lifestyle, oral hypoglycaemics, insulin. Consider tacrolimus dose reduction / switch to cyclosporin.

Hypertension

Affects 60–80% of transplant recipients. Causes: CNI vasospasm, steroids, weight gain, native kidney contribution. Tx: CCBs (amlodipine — first choice; also partially counters CNI vasoconstriction), ACEi/ARB (caution with GFR/K+). Target BP <130/80.

Dyslipidaemia

Steroids + CNIs (especially cyclosporin) + mTOR inhibitors all worsen lipid profile. Statin therapy (pravastatin preferred — less CYP3A4 interaction). Statins are reno-protective. Monitor LFT + CK.

CKD — Chronic Kidney Disease

CNI nephrotoxicity causes CKD in all solid organ recipients (not just kidney). 10–20% of heart/liver transplant patients develop severe CKD requiring dialysis. Monitor creatinine, GFR, proteinuria at every visit. Minimise CNI where possible.

Rejection Episodes — Management Summary

Type	Timing	First-line Treatment
Hyperacute	Minutes–hours	Graft removal (irreversible)
Acute Cellular	Days–3 months	IV Methylprednisolone 500mg x3 days; if steroid-resistant → ATG
ABMR	Any time	Plasmapheresis + IVIG + Rituximab ± steroids
Chronic	Months–years	Optimise IS, control BP, avoid nephrotoxins; no cure

Nursing responsibilities during rejection treatment:

Monitor blood glucose (pulse steroids cause hyperglycaemia)
Fluid balance — pulse steroids cause fluid retention
Infection surveillance — increased immunosuppression risk
Psychological support — rejection is frightening for patient
Ensure tacrolimus levels therapeutic throughout

GCC Context & Exam Prep

Organ Donation in the GCC

Historically low deceased donor rates vs Western countries — driven by religious/cultural factors, lack of public awareness, and legislative gaps.

Religious Considerations:

Islamic scholars in most GCC states have issued fatwas permitting organ donation as an act of charity (sadaqah jariyah). Saudi Arabia's Council of Senior Scholars, UAE Fatwa Council, and Kuwait's Fatwa Board have all approved deceased and living donation under specific conditions. Concept of "brain death" as legal death varies — requires ongoing community education.

Saudi Arabia:

Most advanced transplant programme in region. Saudi Center for Organ Transplantation (SCOT) established 1986. KAMC (King Abdulaziz Medical City) and KFSHRC are regional centres of excellence. Increasing deceased donor rates post-2015.

Living Donation Culture:

Living-related kidney donation is culturally acceptable and common in Gulf families — sense of family obligation is strong. Paired exchange programmes emerging. Altruistic donation increasing.

Commercial Organ Trade Awareness:

Iranian kidney trade (semi-legal regulated market) is known. Nurses must be aware of transplant tourism — patients may return from abroad with poorly documented transplants, unknown immunosuppression, and higher risk of transmitted infection.

DHA / DOH / SCFHS Competencies

Dubai Health Authority (DHA), Department of Health Abu Dhabi (DOH), and Saudi Commission for Health Specialties (SCFHS) nurse licensing exams test transplant nursing competencies.

Core exam topics:

Rejection types, presentations & management
Immunosuppression monitoring (tacrolimus levels)
CMV prophylaxis dosing & monitoring
Post-transplant infection & malignancy
NODAT — risk factors & monitoring
Nursing care for biopsy & USS Doppler
Brain death criteria & donor family care

Ramadan Considerations:

Tacrolimus is given BD (every 12 hours). During Ramadan fasting, timing adjustment is critical — many patients shift medication times to Iftar and Suhoor. Studies show Ramadan fasting does not significantly impact tacrolimus pharmacokinetics IF timing is consistent. Nurses must counsel patients not to miss doses, maintain 12-hour intervals, and avoid dietary changes (dates in large quantities may affect levels). Patients with unstable graft function may be exempt from fasting (Islamic ruling — exemption for illness).

Interactive Rejection Type Identifier

Select clinical parameters to identify the most likely rejection type and management pathway.

Time Since Transplant

Dominant Clinical Features

Biopsy / Investigations

Exam Quick Reference — High-Yield Facts

Numbers to Know

Urine output target: >50 ml/hr
Tacrolimus early target: 8–12 ng/ml
Tacrolimus maintenance: 4–8 ng/ml
Heart CIT: 4–6 hours
Kidney CIT: 24–36 hours
MELD listing threshold: >15
UKELD listing: >49
CVP target: 8–12 cmH₂O

Drug Danger Alerts

Azathioprine + Allopurinol = FATAL toxicity
Voriconazole + Tacrolimus = level x5-10
Rifampicin + Tacrolimus = sub-therapeutic
MMF = teratogenic — contraception mandatory
Atropine = ineffective in heart Tx bradycardia
Grapefruit juice + CNI = raised levels

Rejection — 3-Second Recall

Hyperacute = pre-formed Ab, hours, surgery
Acute Cellular = T-cells, weeks, steroids
ABMR = DSA, C4d, plasmapheresis
Chronic = IF/TA, years, no cure

Prophylaxis Summary

CMV: Valganciclovir
PCP: Co-trimoxazole
Candida: Fluconazole